Cytokine Release Syndrome During Sequential Treatment With Immune Checkpoint Inhibitors and Kinase Inhibitors for Metastatic Melanoma

Skin Cancer

Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma

Clin Kidney J.

Murakami N, Borges TJ, Yamashita M, Riella LV

doi: 10.1093/ckj/sfw024.

Gastrointestinal CancerLung, Respiratory and Thoracic CancerSkin Cancer

Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors – an autopsy study

J Immunother Cancer.

Koelzer VH, Rothschild SI, Zihler D, Wicki A, Willi B, Willi N, Voegeli M, Cathomas G, Zippelius A, Mertz KD

doi: 10.1186/s40425-016-0117-1.

Lung, Respiratory and Thoracic Cancer

Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials: A Meta-analysis

JAMA Oncol.

Blumenthal GM, Zhang L, Zhang H, Kazandjian D, Khozin S, Tang S, Goldberg K, Sridhara R, Keegan P, Pazdur R

doi: 10.1001/

Skin Cancer

Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma

Melanoma Res.

Yip RHL, Lee LH, Schaeffer DF, Horst BA, Yang HM

doi: 10.1097/CMR.

Skin Cancer

Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition

Eur J Cancer.

Heppt MV, Heinzerling L, Kähler KC, Forschner A, Kirchberger MC, Loquai C, Meissner M, Meier F, Terheyden P, Schell B, Herbst R, Göppner D, Kiecker F, Rafei-Shamsabadi D, Haferkamp S, Huber MA, Utikal J, Ziemer M, Bumeder I, Pfeiffer C, Schäd SG, Schmid-Tannwald C, Tietze JK, Eigentler TK, Berking C

doi: 10.1016/j.ejca.2017.05.038.

Further Publications

Management of Cutaneous Immune-Related Adverse Events in Patients With Cancer Treated With Immune Checkpoint Inhibitors: A Systematic Review

JAMA Oncol

Nadelmann ER, Yeh JE, Chen ST

doi: 10.1001/jamaoncol.2021.4318

Genitourinary Cancer

Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer

Prostate.

Markowski MC, Shenderov E, Eisenberger MA, Kachhap S, Pardoll DM, Denmeade SR, Antonarakis ES

doi: 10.1002/pros.23955.

Skin Cancer

A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib

BMC Cancer.

Maleka A, Åström G, Byström P, Ullenhag GJ.

doi: 10.1186/s12885-016-2657-7.

Gastrointestinal CancerSkin Cancer

Mismatch repair deficient metastatic colon cancer and urothelial cancer: a case report of sequential immune checkpoint therapy

Cancer Biol Ther.

Ghatalia P, Nagarathinam R, Cooper H, Geynisman DM, El-Deiry WS

doi: 10.1080/

Related content

Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma

Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors – an autopsy study

Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials: A Meta-analysis

Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma

Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition

Management of Cutaneous Immune-Related Adverse Events in Patients With Cancer Treated With Immune Checkpoint Inhibitors: A Systematic Review

Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer

A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib

Mismatch repair deficient metastatic colon cancer and urothelial cancer: a case report of sequential immune checkpoint therapy